Dyspnea in Chemical War Victims Exposed to Sulfur Mustard: A Narrative Review of Respiratory Distress in Survivors
Health Science Reports · 2026-07 · 9 (7)
DOI: 10.1002/hsr2.72791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 10.07.2026. Verfasst von Mahboobeh Ghasemzadeh Rahbardar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shahid Hasheminejad Hospital, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims Dyspnea, a prevalent symptom among victims of chemical warfare exposed to sulfur mustard, presents substantial physiological and pharmacological challenges. Inhaling sulfur mustard in warfare may result in significant respiratory distress, emphasizing the necessity of investigating the underlying processes and treatment options for dyspnea in this population.
Methods
A comprehensive search was performed on Google Scholar, PubMed, and Scopus with no time constraints, including keywords such as “chemical war victims”, “veterans”, “respiratory distress”, “dyspnea”, and “sulfur mustard”. Relevant articles were reviewed to collect information about dyspnea in chemical war victims.
Results
Various studies reported the dyspnea due to exposure to sulfur mustard. Dyspnea in chemical war victims is triggered by physiological mechanisms such as airway inflammation, pulmonary edema, and oxidative stress. Pharmacological interventions including bronchodilators, corticosteroids, and oxygen therapy play an essential role in controlling dyspnea. These therapies have been found to be beneficial in reducing respiratory distress and improving the quality of life in affected individuals.
Conclusion
Dyspnea in chemical warfare victims exposed to sulfur mustard is a complex condition that requires a multidisciplinary approach for optimal management. Understanding the physiological mechanisms that underlying dyspnea and applying appropriate pharmacological therapies are essential to achieving better respiratory outcomes in this patient population. Continued research and collaborative efforts are critical to provide care and support for people suffering from dyspnea as a result of sulfur mustard exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shahid Hasheminejad Hospital, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran.
- Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran.
- Pharmacological Research Center of Medicinal Plants, Basic Sciences Research Institute, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran.
- Department of Biological and Medical Sciences Faculty of Health and Life Sciences, Oxford Brookes University Oxford UK.
- Applied Biomedical Research Center, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran.
- Department of Physiology Faculty of Medicine, Mashhad University of Medical Sciences Mashhad Islamic Republic of Iran.
ORCID-Profile: Mahboobeh Ghasemzadeh Rahbardar, Mohammad Hossein Boskabady
Zitieren
APA
Ghasemzadeh Rahbardar, M., Moosavi, S. H., & Boskabady, M. H. (2026). Dyspnea in Chemical War Victims Exposed to Sulfur Mustard: A Narrative Review of Respiratory Distress in Survivors. Health Science Reports, 9(7). https://doi.org/10.1002/hsr2.72791
Vancouver
Ghasemzadeh Rahbardar M, Moosavi SH, Boskabady MH. Dyspnea in Chemical War Victims Exposed to Sulfur Mustard: A Narrative Review of Respiratory Distress in Survivors. Health Science Reports. 2026;9(7). doi:10.1002/hsr2.72791
BibTeX
@article{GhasemzadehRahbardar2026,
author = {Ghasemzadeh Rahbardar, Mahboobeh and Moosavi, Shakeeb H and Boskabady, Mohammad Hossein},
title = {Dyspnea in Chemical War Victims Exposed to Sulfur Mustard: A Narrative Review of Respiratory Distress in Survivors},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {7},
doi = {10.1002/hsr2.72791}
}
EUVIMED